Breast cancer, malignant (ICD10 C50): women
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
73.8% |
79.8% |
85.0% |
85.4% |
||||||||
|
(unstandardized) |
(72.5-75.1%) |
(78.8-80.8%) |
(83.8-86.1%) |
(84.3-86.5%) |
||||||||
|
all 15-99 |
71.7% |
76.8% |
81.8% |
82.1% |
76.2% |
79.0% |
||||||
|
(age-standardized)# |
(68.3-74.9%) |
(74.1-79.2%) |
(78.6-84.7%) |
(79.0-84.9%) |
(74.3-78.2%) |
(78.1-80.0%) |
||||||
|
15-44 |
75.7% |
82.0% |
84.9% |
85.5% |
||||||||
|
(72.7-78.3%) |
(79.7-84%) |
(82.2-87.1%) |
(82.9-87.7%) |
|||||||||
|
45-54 |
78.6% |
84.8% |
88.4% |
90.0% |
||||||||
|
(76.3-80.6%) |
(83.2-86.2%) |
(86.5-90.0%) |
(88.2-91.5%) |
|||||||||
|
55-64 |
73.0% |
80.9% |
87.5% |
87.7% |
||||||||
|
(70.4-75.4%) |
(79.1-82.5%) |
(85.6-89.1%) |
(85.7-89.4%) |
|||||||||
|
65-74 |
70.2% |
75.4% |
81.7% |
81.6% |
||||||||
|
(67.0-73.2%) |
(72.8-77.8%) |
(78.6-84.4%) |
(78.6-84.3%) |
|||||||||
|
75-99 |
68.5% |
70.2% |
74.0% |
74.0% |
||||||||
|
(63.7-73.2%) |
(66.3-73.9%) |
(69.1-78.7%) |
(69.2-78.6%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005-2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x7000, 45-54 x12000, 55-64 x23000, 65-74 x29000, 75-99 x29000) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
Cancer registration is a dynamic process and information is continually updated on our database. |
|
|
As a result, the figures given here may not correspond exactly to those in previous reports or to those previously shown on our website. |
|
|
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|